# MOONLAKE IMMUNOTHERAPEUTICS (MLTX)

> Institutional ownership reported to the SEC as of Q3 2026, from Form 13F filings. Source: https://holderbook.com/stocks/MLTX/

- Reporting holders: 3
- Reported value: $2.6M
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [CONGRESS ASSET MANAGEMENT CO](https://holderbook.com/funds/897378-congress-asset-management-co/) | $2.6M | 223,883 | 0.0% | 9 |
| [Farther Finance Advisors, LLC](https://holderbook.com/funds/1992825-farther-finance-advisors-llc/) | $2.2K | 191 | 0.0% | 5 |
| [GAMMA Investing LLC](https://holderbook.com/funds/2010235-gamma-investing-llc/) | $164 | 14 | 0.0% | 2 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2026 | 3 | $2.6M |
| Q2 2026 | 174 | $1.5B |
| Q1 2026 | 148 | $1.2B |
| Q4 2025 | 131 | $797.2M |
| Q3 2025 | 147 | $317.1M |
| Q2 2025 | 139 | $2.8B |
| Q1 2025 | 140 | $2.4B |
| Q4 2024 | 120 | $3.4B |
| Q3 2024 | 113 | $3.1B |
| Q2 2024 | 111 | $2.7B |
| Q1 2024 | 120 | $3.1B |
| Q4 2023 | 131 | $3.6B |